Performance of the American Thyroid Association Risk Classification in a Single Center Cohort of Pediatric Patients with Differentiated Thyroid Cancer: A Retrospective Study

Raad Alwithenani, Sarah DeBrabandere, Irina Rachinsky, S Danielle MacNeil, Mahmoud Badreddine, Stan Van Uum, Raad Alwithenani, Sarah DeBrabandere, Irina Rachinsky, S Danielle MacNeil, Mahmoud Badreddine, Stan Van Uum

Abstract

Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy in children. Retrospective studies show conflicting results regarding predictors of persistent and recurrent disease after initial therapy. In 2015, the American Thyroid Association (ATA) proposed a clinical classification system to identify pediatric thyroid cancer patients at risk for persistent/recurrent disease.

Material and methods: We retrospectively included all patients in our registry diagnosed with papillary DTC at ≤ 18 years of age. We analyzed the prognostic performance of the ATA classification and other risk factors for predicting response to initial treatment and final outcome in pediatric DTC.

Results: We included 41 patients, 34 females and 7 males, diagnosed with papillary DTC at a mean (SD) age of 16.2 (1.8) years. Based on the ATA pediatric risk classification, patients were categorized as low (61%), intermediate (10%), or high risk (29%). The median follow-up period was 7.3 (1-41) years. After initial treatment, disease free status was achieved in 92%, 50%, and 42% of the low, intermediate, and high risk groups, respectively (P <0.01). At the last visit, persistent disease was present in 12%, 25%, and 33% (P=0.27). Assessing other risk factors, only the presence of distant metastases at diagnosis resulted in increased presence of persistent disease at last follow-up (P=0.03).

Conclusion: This study supports the clinical relevance of the ATA risk classification for predicting the response to initial treatment. There was no clear prediction of long-term outcome, but this may be due to limited power caused by the small number of patients.

Figures

Figure 1
Figure 1
Clinical course pediatric patients with well-differentiated thyroid cancer.
Figure 2
Figure 2

References

    1. Alzahrani A. S., Alkhafaji D., Tuli M., et al. Comparison of differentiated thyroid cancer in children and adolescents (<20 years) with young adults. Clinical Endocrinology. 2016;84(4):571–577.
    1. Dinauer C. A., Breuer C., Rivkees S. A. Differentiated thyroid cancer in children: diagnosis and management. Current Opinion in Oncology. 2008;20(1):59–65. doi: 10.1097/cco.0b013e3282f30220.
    1. Enomoto Y., Enomoto K., Uchino S., Shibuya H., Watanabe S., Noguchi S. Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World Journal of Surgery. 2012;36(6):1241–1246. doi: 10.1007/s00268-012-1558-4.
    1. Huang C., Chao T., Hseuh C., et al. Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer. Pediatric Surgery International. 2012;28(5):489–494. doi: 10.1007/s00383-012-3054-1.
    1. Park S., Jeong J. S., Ryu H. R., et al. Differentiated thyroid carcinoma of children and adolescents: 27-year experience in the Yonsei University Health System. Journal of Korean Medical Science. 2013;28(5):693–699. doi: 10.3346/jkms.2013.28.5.693.
    1. Mihailovic J., Nikoletic K., Srbovan D. Recurrent disease in juvenile differentiated thyroid carcinoma: Prognostic factors, treatments, and outcomes. Journal of Nuclear Medicine. 2014;55(5):710–717. doi: 10.2967/jnumed.113.130450.
    1. Al-Qahtani K. H., Tunio M. A., Al Asiri M., et al. Clinicopathological features and treatment outcomes of differentiated thyroid cancer in Saudi children and adults. Journal of Otolaryngology - Head and Neck Surgery. 2015:44–48.
    1. Pires B. P., Alves P. A. G., Bordallo M. A., et al. Prognostic factors for early and long-term remission in pediatric differentiated thyroid carcinoma: the role of sex, age, clinical presentation, and the newly proposed american thyroid association risk stratification system. Thyroid. 2016;26(10):1480–1487. doi: 10.1089/thy.2016.0302.
    1. Verburg F. A., Mäder U., Luster M., Hänscheid H., Reiners C. Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(9):1390–1398. doi: 10.1007/s00259-015-3076-8.
    1. Silva-Vieira M., Santos R., Leite V., Limbert E. Review of clinical and pathological features of 93 cases of well-differentiated thyroid carcinoma in pediatric age at the Lisbon Centre of the Portuguese Institute of Oncology between 1964 and 2006. International Journal of Pediatric Otorhinolaryngology. 2015;79(8):1324–1329. doi: 10.1016/j.ijporl.2015.06.002.
    1. Kiratli P. Ö., Volkan-Salanci B., Günay E. C., Varan A., Akyüz C., Büyükpamukçu M. Thyroid cancer in pediatric age group: an institutional experience and review of the literature. Journal of Pediatric Hematology/Oncology. 2013;35(2):93–97. doi: 10.1097/MPH.0b013e3182755d9e.
    1. Harach H. R., Williams E. D. Childhood thyroid cancer in England and Wales. British Journal of Cancer. 1995;72(3):777–783. doi: 10.1038/bjc.1995.410.
    1. Vaisman F., Corbo R., Vaisman M. Thyroid carcinoma in children and adolescents—systematic review of the literature. Journal of Thyroid Research. 2011;2011:7. doi: 10.4061/2011/845362.845362
    1. Francis G., Waguespack S. G., Bauer A. J., et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid. 2015;25(7):716–759. doi: 10.1089/thy.2014.0460.
    1. Borson-Chazot F., Causeret S., Lifante J.-C., Augros M., Berger N., Peix J.-L. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World Journal of Surgery. 2004;28(11):1088–1092. doi: 10.1007/s00268-004-7630-y.
    1. Orosco R. K., Hussain T., Brumund K. T., Oh D. K., Chang D. C., Bouvet M. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid. 2015;25(1):125–132. doi: 10.1089/thy.2014.0116.
    1. Qu N., Zhang L., Lu Z., et al. Predictive factors for recurrence of differentiated thyroid cancer in patients under 21 years of age and a meta-analysis of the current literature. Tumor Biology. 2016;37(6):7797–7808. doi: 10.1007/s13277-015-4532-6.
    1. Wada N., Sugino K., Mimura T., et al. Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. Annals of Surgical Oncology. 2009;16(12):3442–3449. doi: 10.1245/s10434-009-0673-4.
    1. Alessandri A. J., Goddard K. J., Blair G. K., Fryer C. J. H., Schultz K. R. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Medical and Pediatric Oncology. 2000;35(1):41–46. doi: 10.1002/1096-911x(200007)35:1<41::aid-mpo7>;2-7.
    1. Edge S. B., Compton C. C. The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology. 2010;17(6):1471–1474. doi: 10.1245/s10434-010-0985-4.
    1. Lazar L., Lebenthal Y., Segal K., et al. Pediatric thyroid cancer: postoperative classifications and response to initial therapy as prognostic factors. The Journal of Clinical Endocrinology & Metabolism. 2016;101(5):1970–1979. doi: 10.1210/jc.2015-3960.
    1. Haugen B. R., Alexander E. K., Bible K. C., et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid: Official Journal of The American Thyroid Association. 2016;26(1):1–133.
    1. Russo M., Malandrino P., Moleti M., et al. Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. Pediatric Blood & Cancer. 2018;65(9)e27226
    1. Jarza̧b B., Handkiewicz-Junak D., Włoch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocrine-Related Cancer. 2005;12(4):773–803. doi: 10.1677/erc.1.00880.
    1. Newman K. D., Black T., Heller G., et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. Annals of Surgery. 1998;227(4):533–541.
    1. Rivkees S. A., Mazzaferri E. L., Verburg F. A., et al. The treatment of differentiated thyroid cancer in children: Emphasis on surgical approach and radioactive iodine therapy. Endocrine Reviews. 2011;32(6):798–826. doi: 10.1210/er.2011-0011.
    1. Welch Dinauer C. A., Tuttle R. M., Robie D. K., et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clinical Endocrinology. 1998;49(5):619–628. doi: 10.1046/j.1365-2265.1998.00584.x.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner